Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Internet Billionaire To Fund First CRISPR Clinical Trial


Sean Parker – founder of Napster and the original president of Facebook – has beat numerous biotech companies to host the first CRISPR clinical trial.

Share this!

June 23, 2016 | by Sarah Massey, M.Sc.

Tweet: #NIH gives the go-ahead to first #CRISPR #clinicaltrial http://ctt.ec/c7gsm+

On Tuesday, a National Institutes of Health (NIH) panel gave the go-ahead to the first ever CRISPR clinical trial funded by internet billionaire, Sean Parker. Despite widespread speculation that the new gene editing technique could be a game-changer for fields like oncology, no other first-in-human clinical trials of the technique has been attempted.

Even with a single abstention, the NIH panel ruled unanimously in favour of allowing the first CRISPR candidate to be tested in a human clinical trial. The study will need to win additional approval from the US Food and Drug Administration (FDA), along with the medical centers where it will be conducted, before the clinical trial can begin recruiting patients.

Sean Parker – founder of Napster and the original president of Facebook – has beat numerous biotech companies to host the first CRISPR clinical trial. Parker – whose net worth is estimated at $2.4 billion – is unaffiliated with any of the pioneering companies in gene editing, including CRISPR Therapeutics, Caribou Biosciences, Edita, Intellia or Novartis.

Pending regulatory approval, the clinical trial will be conducted by a group of researchers at the University of Pennsylvania, and funded by the Parker Institute. In addition, the MD Anderson Cancer Center in Texas and the University of California, San Francisco, will also take part in the groundbreaking study.

One of the collaborators, Dr. Carl June of the University of Pennsylvania, is considered to be a major innovator in the field of T cell biology. He said that the idea behind the project is to make T cells “better than nature made them,” at the Forbes Philanthropy Summit earlier this year.

According to June, the T cells will be edited using CRISPR so that they lack a gene allowing them to respond to an immune system checkpoint protein, known as PD-1. Some cancers hijack this protein which allows them to operate outside the confines of the immune system.

Multiple drugmakers – including Merck, Bristol-Myers Squibb and Roche – have developed PD-1 drugs promising to be more effective cancer therapies. Many oncologists believe that PD-1 checkpoint inhibitors used in combination with CRISPR gene editing and CAR-T cells, represent the future world of cancer treatment.

The NIH-approved CRISPR clinical trial will use the gene editing technique to alter the T cells of approximately 15 cancer patients in an attempt to strengthen their immune systems. Cancer targets for the study include myeloma, sarcoma and melanoma.

Keywords: CRISPR, Clinical Trial, Oncology


Share this with your colleagues!

Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News

FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News

One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


Top 5 Most Impactful Tweets in Life Sciences During the Last Week


EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider

Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology

Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn

eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.